US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

MetaVia Inc

0.7390

+0.00470.64%

Post-market: 0.74000.0010+0.14%19:59 EDT

Volume:598.93K

Turnover:420.88K

Market Cap:6.40M

PE:-0.21

High:0.7479

Open:0.7000

Low:0.6470

Close:0.7343

Loading ...

Overview Company News Filings

U.S. RESEARCH ROUNDUP- Arcutis Biotherapeutics, Artiva Biotherapeutics, Nuvalent

Analysts Are Bullish on These Healthcare Stocks: MetaVia (MTVA), Century Therapeutics (IPSC)

MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial…

Zacks Small Cap Research

MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

MetaVia Reports Positive Phase 2a Results for DA-1241 in Presumed MASH Patients

MT Newswires Live

BRIEF-Metavia Announces Positive Top-Line Results From Its Phase 2A Clinical Trial Of Da-1241 In Patients With Presumed MASH

Metavia Inc - Da-1241 Shows Significant Reduction in Alt Levels at Weeks 4 and 8

THOMSON REUTERS

Metavia Inc - Expects End of Phase 2 Meeting With FDA in First Half of 2025

THOMSON REUTERS

Metavia Inc - Da-1241 Very Well Tolerated With No Drug-Related Serious Adverse Events

THOMSON REUTERS

Metavia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of Da-1241 in Patients With Presumed Mash

THOMSON REUTERS

MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

MTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…

Zacks Small Cap Research

MetaVia to Present at the Emerging Growth Conference in December

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MTVA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"MTVA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTVA\",,,,,undefined,":{"symbol":"MTVA","market":"US","secType":"STK","nameCN":"MetaVia Inc","latestPrice":0.739,"timestamp":1744920000000,"preClose":0.7343,"halted":0,"volume":598934,"hourTrading":{"tag":"盘后","latestPrice":0.74,"preClose":0.739,"latestTime":"19:59 EDT","volume":74920,"amount":56411.927041,"timestamp":1744934392880},"delay":0,"floatShares":2336574,"shares":8654869,"eps":-3.56,"marketStatus":"Market Closed","change":0.0047,"latestTime":"04-17 16:00:00 EDT","open":0.7,"high":0.7479,"low":0.647,"amount":420875.6833253,"amplitude":0.13741,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-3.56,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1470369600000,"exchange":"NASDAQ","adjPreClose":0.7343,"preHourTrading":{"tag":"盘前","latestPrice":0.7155,"preClose":0.7323,"latestTime":"09:29 EDT","volume":15573,"amount":11280.1343616,"timestamp":1744896580399},"postHourTrading":{"tag":"盘后","latestPrice":0.74,"preClose":0.739,"latestTime":"19:59 EDT","volume":74920,"amount":56411.927041,"timestamp":1744934392880},"volumeRatio":0.11595326897331375},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MTVA\",,,,,undefined,":{"symbol":"MTVA","floatShares":2336574,"roa":"-92.24%","roe":"-224.18%","lyrEps":-3.556986,"volumeRatio":0.11595326897331375,"shares":8654869,"dividePrice":0,"high":0.7479,"amplitude":0.13741,"preClose":0.7343,"low":0.647,"week52Low":0.647,"pbRate":"0.81","week52High":5.3,"institutionHeld":0,"latestPrice":0.739,"eps":-3.56,"divideRate":0,"volume":598934,"delay":0,"ttmEps":-3.56,"open":0.7,"prevYearClose":2.03,"prevWeekClose":1.45,"prevMonthClose":1.54,"prevQuarterClose":1.54,"fiveDayClose":1.37,"twentyDayClose":1.55,"sixtyDayClose":1.88},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MTVA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2495354814","title":"U.S. RESEARCH ROUNDUP- Arcutis Biotherapeutics, Artiva Biotherapeutics, Nuvalent","url":"https://stock-news.laohu8.com/highlight/detail?id=2495354814","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495354814?lang=en_us&edition=fundamental","pubTime":"2024-12-30 19:40","pubTimestamp":1735558819,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Arcutis Biotherapeutics, Artiva Biotherapeutics, Nuvalent Dec 30  - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Arcutis Biotherapeutics, Artiva Biotherapeutics and Nuvalent on Monday.  HIGHLIGHTS    * Arcutis Biotherapeutics ARQT.O: H.C. Wainwright initiates coverage with buy rating* Artiva Biotherapeutics ARTV.O: H.C. Wainwright initiates coverage with buy rating * Nuvalent Inc NUVL.O: H.C. Wainwright initiates coverage with buy rating and PT $110Following is a summary of research actions on U.S. companies reported by Reuters on Monday. Stock entries are in alphabetical order* Arcutis Biotherapeutics ARQT.O: H.C. Wainwright initiates coverage with buy rating* Artiva Biotherapeutics ARTV.O: H.C. Wainwright initiates coverage with buy rating * BigBear.ai Holdings Inc BBAI.N: H.C. Wainwright raises PT to $7 from $3* Boston Scientific Corp BSX.N: BTIG raises target price to $101 from $97 * Emerg","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241230:nL4N3NV0FC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0267386448.USD","LU1791710582.SGD","NUVL","LU0345769128.USD","LU2265009873.SGD","LU0950375773.USD","LU1023059063.AUD","LU1804176565.USD","LU2087625088.SGD","LU0823416689.USD","LU2506951958.HKD","LU2506952097.USD","PODD","EBS","LU0122379950.USD","BK4581","LU1989772923.USD","MTVA","BBAI","BK4551","LU1718418525.SGD","BK4587","LU0187121727.USD","IE00BJT1NW94.SGD","BK4588","LU0011850046.USD","LU1153585028.USD","LU0238689110.USD","LU2491050071.SGD","EXEL","ARQT","LU1061106388.HKD","IE0002141913.USD","LU2491050154.USD","BK4139","BK4082","BK4583","LU0882574055.USD","LU2491049909.HKD","LU0353189680.USD","BSX","LU2362541273.HKD","LU0345769631.USD","LU0823417737.USD","ARTV","LU2362540622.SGD","LU2324357040.USD","IE00B4R5TH58.HKD","LU0048584097.USD","BK4539"],"gpt_icon":1},{"id":"2495100775","title":"Analysts Are Bullish on These Healthcare Stocks: MetaVia (MTVA), Century Therapeutics (IPSC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2495100775","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495100775?lang=en_us&edition=fundamental","pubTime":"2024-12-30 19:31","pubTimestamp":1735558271,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MetaVia (MTVA – Research Report) and Century Therape...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-metavia-mtva-century-therapeutics-ipsc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-metavia-mtva-century-therapeutics-ipsc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IPSC","BK4539","MTVA","BK4505","BK4137","HCSG"],"gpt_icon":0},{"id":"2493474532","title":"MTVA:  Compelling Data for DA-1241 in Phase 2a MASH Trial…","url":"https://stock-news.laohu8.com/highlight/detail?id=2493474532","media":"Zacks Small Cap Research","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493474532?lang=en_us&edition=fundamental","pubTime":"2024-12-20 23:24","pubTimestamp":1734708240,"startTime":"0","endTime":"0","summary":"On December 18, 2024, MetaVia Inc.  announced positive topline results from the 16-week Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated steatohepatitis . The trial had two parts: in Part 1, patients were randomized in a 1:2:1 ratio into three treatment groups . In Part 2, patients were randomized in a 2:1 ratio into two treatment groups . The primary efficacy outcome was the change in alanine aminotransferase  levels from baseline at week 16.The following table gives the least square mean ALT values for each treatment group at baseline, 4 weeks, 8 weeks, and 16 weeks. DA-1241 100 mg treatment resulted in a statistically significant decrease in ALT at week 4 and week 8 and was very near statistical significance at week 16. The combination therapy of DA-1241 and sitagliptin did not show a greater effect than monotherapy DA-1241. The company has imagined that DA-1241 will ultimately be used as a combination therapy, however from this data it i","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_3Rf9TBe5Z6QwMk_AfUFTA--~B/aD01NTQ7dz0xODYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/83fdef5b76e05a26a10e7bb8a5e4e542","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_3Rf9TBe5Z6QwMk_AfUFTA--~B/aD01NTQ7dz0xODYwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/83fdef5b76e05a26a10e7bb8a5e4e542"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mtva-compelling-data-da-1241-152400368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4599","LU1878469433.USD","ALT","MTVA","BK4139"],"gpt_icon":0},{"id":"2492512703","title":"MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2492512703","media":"PR Newswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492512703?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:01","pubTimestamp":1734613260,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Dec. 19, 2024 /PRNewswire/ -- MetaVia Inc. ,a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will participate as a Sponsor and Exhibitor at the upcoming, 9th Annual MASH-TAG 2025 Conference. The company's participation follows the recent release of positive top-line 16-week results from the two-part Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119  agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis . The MASH-TAG Conference is taking place January 9-11 at the Chateaux Deer Valley in Park City, Utah. Members of MetaVia's management and clinical team will be available in the Exhibit Hall at the Conference to discuss the results of the Phase 2a clinical trial of DA-1241.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kgC08qjrpJvbPneNdK27Eg--~B/aD03Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/116597eda2a36d52628a741d23461740","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kgC08qjrpJvbPneNdK27Eg--~B/aD03Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/116597eda2a36d52628a741d23461740"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/metavia-participate-9th-annual-mash-130100734.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/metavia-participate-9th-annual-mash-130100734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","OXM","BK4202","MTVA"],"gpt_icon":0},{"id":"2492139429","title":"MetaVia Reports Positive Phase 2a Results for DA-1241 in Presumed MASH Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2492139429","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492139429?lang=en_us&edition=fundamental","pubTime":"2024-12-19 01:25","pubTimestamp":1734542705,"startTime":"0","endTime":"0","summary":"MetaVia  shares were down 26% in recent Wednesday trading after the company reported positive results from its two-part phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated steatohepatitis, or MASH.Part 1 of the trial is evaluating DA-1241, which is a novel g-protein-coupled receptor 119 agonist, against a placebo, while part 2 is examining the efficacy of combining DA-1241 with sitagliptin, a DPP-4 inhibitor.The trial showed that DA-1241 resulted in a statistically significant reduction in alanine transaminase levels at weeks four and eight, with a near-significant reduction observed at week 16, the company said, adding that statistically significant results were also observed in several secondary endpoints, including reductions in controlled attenuation parameter and hemoglobin A1C.The drug also demonstrated a strong safety profile, with mostly mild adverse events and no drug-related serious adverse events. MetaVia said that out of 109 randomi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2492185601","title":"BRIEF-Metavia Announces Positive Top-Line Results From Its Phase 2A Clinical Trial Of Da-1241 In Patients With Presumed MASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2492185601","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492185601?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:36","pubTimestamp":1734528998,"startTime":"0","endTime":"0","summary":"Dec 18  - MetaVia Inc   :   * METAVIA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM ITS PHASE 2A CLINICAL TRIAL OF DA-1241 IN PATIENTS WITH PRESUMED MASH   * DA-1241 VERY WELL TOLERATED WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS   * DA-1241 SHOWS SIGNIFICANT REDUCTION IN ALT LEVELS AT WEEKS 4 AND 8   * DA-1241 100MG SHOWS SIGNIFICANT IMPROVEMENTS IN CAP SCORE AT WEEK 16   * DA-1241 100MG SHOWS SIGNIFICANT REDUCTIONS IN HBA1C AT WEEK 16   * EXPECTS END OF PHASE 2 MEETING WITH FDA IN FIRST HALF OF 2025Source text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BRIEF-Metavia Announces Positive Top-Line Results From Its Phase 2A Clinical Trial Of Da-1241 In Patients With Presumed MASH","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2492700188","title":"Metavia Inc - Da-1241 Shows Significant Reduction in Alt Levels at Weeks 4 and 8","url":"https://stock-news.laohu8.com/highlight/detail?id=2492700188","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492700188?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:01","pubTimestamp":1734526862,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA5KYHRG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2492188727","title":"Metavia Inc - Expects End of Phase 2 Meeting With FDA in First Half of 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2492188727","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492188727?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:01","pubTimestamp":1734526862,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA5KYHRG:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MTVA","BK4139"],"gpt_icon":0},{"id":"2492188722","title":"Metavia Inc - Da-1241 Very Well Tolerated With No Drug-Related Serious Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2492188722","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492188722?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:01","pubTimestamp":1734526862,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA5KYHRG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2492188707","title":"Metavia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of Da-1241 in Patients With Presumed Mash","url":"https://stock-news.laohu8.com/highlight/detail?id=2492188707","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492188707?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:01","pubTimestamp":1734526862,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUA5KYHRG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","MTVA"],"gpt_icon":0},{"id":"2492183515","title":"MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2492183515","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492183515?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:01","pubTimestamp":1734526860,"startTime":"0","endTime":"0","summary":"DA-1241 Demonstrated Direct Hepatic Action in Addition to Its Glucose Lowering Effect. Patients Treated with DA-1241 100mg Achieved Statistically Significant Reduction in ALT Levels at Weeks 4 and 8, and a Near Statistically Significant Reduction at Week 16. DA-1241 100mg Demonstrated Statistically Significant Improvements in CAP Score at Week 16. Awaiting Data on Other Exploratory Endpoints Including MRI-PDFF. Additional Findings to be Submitted for Upcoming Scientific Conferences. * Confidence interval excludes 0, suggesting a statistically meaningful difference. p < 0.05 vs. placebo. Proportion of Subjects with Normalized ALT <30 IU/L at Week 16. LS Mean CAP, VCTE, FAST score Changes from Baseline at Week 16","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kgC08qjrpJvbPneNdK27Eg--~B/aD03Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/116597eda2a36d52628a741d23461740","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kgC08qjrpJvbPneNdK27Eg--~B/aD03Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/116597eda2a36d52628a741d23461740"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/metavia-announces-positive-top-line-130100214.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/metavia-announces-positive-top-line-130100214.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OXM","BK4585","BK4599","IE00BFXG0V08.USD","BK4139","MTVA","BK4104","LU1878469433.USD","AST","FAST","IE00B5TLWC47.USD","IE00BYQQ9H92.USD","BK4588","ALT","BK4567","GGT","BK4202"],"gpt_icon":0},{"id":"2488923448","title":"MTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…","url":"https://stock-news.laohu8.com/highlight/detail?id=2488923448","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488923448?lang=en_us&edition=fundamental","pubTime":"2024-12-03 19:33","pubTimestamp":1733225580,"startTime":"0","endTime":"0","summary":"On November 18, 2024, NeuroBo Pharmaceuticals, Inc.  announced a strategic realignment ahead of upcoming clinical milestones along with a corporate name change to MetaVia Inc. . The change went into effect on November 29, 2024. We are republishing the latest research report under the MTVA ticker.MetaVia Inc. is developing DA-1241 as a treatment for metabolic dysfunction-associated steatohepatitis . DA-1241 is a novel chemical entity that selectively activates GPR119, stimulates the secretion of insulin and incretin hormones such as glucagon-like peptide-1 , reduces plasma glucose levels without causing hypoglycemia, and lowers plasma lipid levels of both triglycerides and cholesterol.MAD Part 2 Results from Phase 1 Trial of DA-1726 Expected in 1Q25. The multiple ascending dose  Part 2 of the trial is ongoing, with the first patient enrolled in June 2024. A total of 36 individuals are expected to be enrolled in Part 2 of the trial in a 6:3 ratio across four dosing cohorts. Each particip","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6BnuZucQR4TI36e.yZdpVQ--~B/aD04NTY7dz0xMzc0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/daa58845a8f57cfe3cbb544b5bfe2eda","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6BnuZucQR4TI36e.yZdpVQ--~B/aD04NTY7dz0xMzc0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/scr.zacks.com/daa58845a8f57cfe3cbb544b5bfe2eda"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/mtva-neurobo-becomes-metavia-topline-113300772.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALT","BK4599","BK4181","PK","BK4218","BK4139","MTVA","LU1878469433.USD"],"gpt_icon":0},{"id":"2488968759","title":"MetaVia to Present at the Emerging Growth Conference in December","url":"https://stock-news.laohu8.com/highlight/detail?id=2488968759","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488968759?lang=en_us&edition=fundamental","pubTime":"2024-12-02 21:01","pubTimestamp":1733144460,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., Dec. 2, 2024 /PRNewswire/ --MetaVia Inc. ,a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announcedthat Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a company update at the Emerging Growth Conference on Wednesday, December 4, 2024 at 4:10 pm ET.After the presentation, MetaVia management will open the floor for questions. Please submit your questions in advance to questions@emerginggrowth.com,or ask your questions during the event.Please register using this linkto attend the virtual conference and receive any updates that are released. To schedule a meeting with management outside of the conference, please contact Michael Miller at mmiller@rxir.com.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kgC08qjrpJvbPneNdK27Eg--~B/aD03Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/116597eda2a36d52628a741d23461740","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kgC08qjrpJvbPneNdK27Eg--~B/aD03Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/116597eda2a36d52628a741d23461740"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/metavia-present-emerging-growth-conference-130100487.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/metavia-present-emerging-growth-conference-130100487.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OXM","MTVA","BK4202"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":33,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MTVA\",params:#limit:5,,,undefined,":[{"date":"2025-03-20","symbol":"MTVA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742457600000,"name":null,"time":"Pre-Market","dateTimestamp":1742443200000,"actualEps":null},{"market":"US","date":"2024-11-07","symbol":"MTVA","fiscalQuarterEnding":"2024/09","expectedEps":-0.82,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.55},{"market":"US","date":"2024-08-14","symbol":"MTVA","fiscalQuarterEnding":"2024/06","expectedEps":-1.38,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723608000000,"reportTimeType":"pre","actualEps":-1.85},{"market":"US","date":"2024-05-09","symbol":"MTVA","fiscalQuarterEnding":"2024/03","expectedEps":-0.95,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715227200000,"reportTimeType":"pre","actualEps":-1.32},{"date":"2024-03-28","symbol":"MTVA","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711612800000,"name":null,"time":"Pre-Market","dateTimestamp":1711598400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MTVA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MTVA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1735617600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MTVA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MTVA","date":"2025-04-17","current":-0.23033,"percent":1,"low":-0.807761,"twenty":-0.636267,"median":-0.537471,"eighty":-0.476844,"high":-0.23033,"avg":-0.55302,"sd":0.106731,"marketCap":6355270},"quantilePoints":[{"date":"2024-12-06","current":-0.714557,"twenty":-0.800304,"median":-0.792227,"eighty":-0.751814,"marketCap":19816823},{"date":"2024-12-13","current":-0.716111,"twenty":-0.79347,"median":-0.728538,"eighty":-0.7158,"marketCap":19859903},{"date":"2024-12-20","current":-0.546792,"twenty":-0.767348,"median":-0.716111,"eighty":-0.685354,"marketCap":15164177},{"date":"2024-12-27","current":-0.562326,"twenty":-0.746234,"median":-0.70213,"eighty":-0.556112,"marketCap":15594978},{"date":"2025-01-03","current":-0.655529,"twenty":-0.730091,"median":-0.686597,"eighty":-0.553006,"marketCap":18179781},{"date":"2025-01-10","current":-0.661742,"twenty":-0.733198,"median":-0.686597,"eighty":-0.564811,"marketCap":18352101},{"date":"2025-01-17","current":-0.58718,"twenty":-0.720771,"median":-0.663296,"eighty":-0.577238,"marketCap":16284258},{"date":"2025-01-24","current":-0.602714,"twenty":-0.720771,"median":-0.647762,"eighty":-0.584073,"marketCap":16715059},{"date":"2025-01-31","current":-0.584073,"twenty":-0.717664,"median":-0.630675,"eighty":-0.584073,"marketCap":16198098},{"date":"2025-02-07","current":-0.562326,"twenty":-0.716111,"median":-0.615141,"eighty":-0.562326,"marketCap":15594978},{"date":"2025-02-14","current":-0.512617,"twenty":-0.714557,"median":-0.608927,"eighty":-0.546792,"marketCap":14216416},{"date":"2025-02-21","current":-0.509511,"twenty":-0.704615,"median":-0.602714,"eighty":-0.540578,"marketCap":14130256},{"date":"2025-02-28","current":-0.453589,"twenty":-0.699297,"median":-0.58718,"eighty":-0.518583,"marketCap":12579374},{"date":"2025-03-07","current":-0.487763,"twenty":-0.688995,"median":-0.584073,"eighty":-0.503297,"marketCap":13527135},{"date":"2025-03-14","current":-0.467569,"twenty":-0.681626,"median":-0.568539,"eighty":-0.495468,"marketCap":12967095},{"date":"2025-03-21","current":-0.48401,"twenty":-0.667956,"median":-0.562326,"eighty":-0.487763,"marketCap":13354815},{"date":"2025-03-28","current":-0.48933,"twenty":-0.662363,"median":-0.546792,"eighty":-0.487763,"marketCap":13501595},{"date":"2025-04-04","current":-0.47992,"twenty":-0.656772,"median":-0.540578,"eighty":-0.485083,"marketCap":13241949},{"date":"2025-04-11","current":-0.429732,"twenty":-0.643102,"median":-0.539025,"eighty":-0.482756,"marketCap":11857170},{"date":"2025-04-17","current":-0.23033,"twenty":-0.636267,"median":-0.537471,"eighty":-0.476844,"marketCap":6355270}],"updateTime":1745134276997}}}